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1. Introduction
Heart failure (HF) is a worldwide issue. This syndrome is estimated to be present in more than
37 million of patients in the world [1]. In Western countries, this is mainly related to ischemic
heart disease, hypertension and diabetes mellitus. In developing and Third-World countries,
the causes are more varied. There is still a high incidence of rheumatic disease and end-stage
valvulopathies. However, ischemic heart disease is increasing due to the spread of risk factors
(diabetes, hypercholesterolemia, smoke). Progressive ageing of the population is another
factor that has greatly increased the incidence of HF over the years. The number of hospital
admissions with HF as a diagnosis in the USA tripled from 1.27 million in 1979 to 3.86 million
in 2004 [2].
Nevertheless, despite major improvements of medical, interventional and surgical treatment,
the mortality of the patients with advanced HF is still high; a recent analysis of Medicare
patients showed a 50% mortality at 3 years [3].
Apart from the clinical burden in terms of morbidity and mortality, the financial impact of HF
is impressive. A forecasting of the impact of heart failure in the USA showed an increase of
total expenditure from 21 billion to 53 billion between 2012 and 2030 [4].
2. Classifications
The American College of Cardiology and AHA practice guidelines for chronic HF published in
2001 proposed a classification that includes four stages of HF [5]. Stages A and B are early phases
without an overt syndrome and are alerting states. Stage A patients are at risk for HF related to
conditions such as hypertension, atherosclerotic heart disease and diabetes mellitus. Stage B
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patients have developed structural heart disease from a variety of potential insults to the heart
muscle, i.e. myocardial infarctions or valvular heart diseases, but still asymptomatic. Stages C
and D are the symptomatic phases of HF. Therapeutic interventions, including dietary salt
restriction, medications and implantable devices (pacemakers and defibrillators), are indicated
for patients with symptomatic heart failure (stage C). In the end stages of HF (stage D), patients
present marked symptoms at rest or with minimal activity despite optimal medical therapy.
Another important classification of HF is based on the left ventricular ejection fraction (EF)
value. We generally consider the HF as a low (reduced, <40%) EF syndrome (HFrEF). There is
indeed an almost equal number of patients in HF with a preserved EF (>50%) (HFpEF). In
between we find patients with moderately reduced EF (40–49%, HFmrEF). The HFpEF shows
normally a diastolic LV dysfunction [6].
3. Diagnosis
The diagnosis of HF may be sometimes challenging. There are the classical signs and symp-
toms that represent the definition of the syndrome (shortness of breath, fatigue, elevated JVP,
crackles, ankle swelling, gallop rhythm). However, there are also less specific ones; for
instance, depression could be a symptom of HF, as well as confusion, in particular in the
elderly. In the older people, in particular, there may be other conditions that make the diagno-
sis more difficult (i.e. chronic pulmonary diseases). In stable patients, the measurements of
natriuretic peptides may help. NT-proBNP level > 125 pg/mL or BNP level > 35 pg/mL should
prompt the request for an echocardiography if one of the classical signs or symptoms is present
[7]. Transthoracic echocardiography represents the cheapest assessment that may give a cer-
tain diagnosis. Care should be taken when an HFpEF is present. In these patients a diastolic,
dysfunction should be demonstrated to make diagnosis.
Other imaging modalities could be used in doubtful cases as magnetic resonance imaging
(MRI) or gated single-photon emission CT (SPECT). MRI is extremely accurate in measuring
volumes, masses and EF of both ventricles. The gadolinium-enhanced modality allows a
precise assessment of fibrosis, scars and inflammation (myocarditis). Amyloidosis, sarcoidosis,
Chagas disease, non-compaction cardiomyopathy and haemochromatosis are similarly well
defined by MRI [8].
4. Prevention
The value of prevention in HF has is now well established. The most effective way is a
thorough control of hypertension if present [9]. A mild alcohol intake and a regular physical
activity are also extremely beneficial. A prompt pharmacological intervention in asymptomatic
patients is also recommended; the use of ACE inhibitors has clearly shown to reduce mortality
and hospital admissions in patients without a clinically evident HF but with a low EF [10].
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5. Treatment
The pharmacological treatment of HF is clearly codified in several national and international
guidelines [11]. The cornerstones remain the diuretics, beta blockers, ACE inhibitors and
mineralocorticoid receptor antagonists; recently new medications have been used with prom-
ising results in subcategories of HF patients like the ivabradine and sacubitril valsartan.
However, a multidisciplinary discussion about every single patient and a close monitoring of
the clinical effectiveness are important [12]. The management of acute HF decompensation is
more complex and less codified.
HF patients may benefit of a few non-pharmacological interventions able mainly to improve
survival. The mortality in HF is to be cancelled not infrequently sudden and related to arrhyth-
mic events. The most recent guidelines about HF clearly states that ‘An implantable
cardioverter-defibrillator (ICD) is recommended to reduce the risk of sudden death and all-
cause mortality in patients who have recovered from a ventricular arrhythmia causing
haemodynamic instability, and who are expected to survive for >1 year with good functional
status’. This is a recommendation IA, therefore with a very strong evidence. Moreover, the ICD
is also strongly recommended in patients with an EF <35% after 3 months of optimal medical
treatment and when life expectancy is more than 1 year [7]. On the contrary, when the patient
is in NYHA Class IV and is not a candidate for cardiac resynchronisation therapy (CRT),
ventricular assist device (VAD) or heart transplantation, the ICD is formally contraindicated.
The cardiac resynchronisation therapy (CRT) is a non-pharmacological/non-surgical treatment
that represents a consistent adjunct for HF management. It consists in a synchronous pacing of
both ventricles. There are clear indications, mainly related to ECG parameters and the clinical
status of the patient [7]. Nowadays, the CRT devices have frequently defibrillating or pacing
features. This treatment has shown to improve the quality of life and, partly, the survival of HF
patients [13, 14]. However, there are non-responders to CRT that sometimes are difficult to
identify before the implantation. As a rule, ischemic patients respond less favourably; on the
contrary, female subjects are better responders.
The last resource for end-stage HF patients or when a refractory acute HF develops are
mechanical circulatory support devices. In case of acute decompensation, extracorporeal,
non-durable life support systems can be used to unload the ventricles. When the condition is
chronic, a left ventricular assist device (LVAD) can be indicated. There are five conditions [15]
that may prompt the consideration of a MCS:
A. Bridge to decision or bridge to bridge: The use of short-termMCS (ECMO) in patients with
cardiogenic shock until haemodynamics and end-organ perfusion are stabilised, contrain-
dications for long-term MCS are excluded (brain damage after resuscitation) and addi-
tional therapeutic options including long-term VAD therapy or heart transplant can be
evaluated.
B. Bridge to candidacy: The use of MCS (usually LVAD) to improve end-organ function in
order to make an ineligible patient eligible for heart transplantation.
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C. Bridge to transplantation: The use of MCS (LVAD or BiVAD) to keep the patient alive who
is otherwise at high risk of death before transplantation until a donor organ becomes
available.
D. Bridge to recovery: The use of MCS (typically LVAD) to keep the patient alive until the
heart recovers enough to remove MCS.
E. Destination therapy: The long-term use of MCS (LVAD) as an alternative to transplanta-
tion in patients with end-stage HF ineligible for transplantation or long-term waiting for
heart transplantation.
The technology behind LVAD is continuously evolving, and smaller and less invasive models
are expected in the next few years.
Heart transplantation still represents a viable treatment modality for end-stage heart failure.
Major issues are the shortage of donor organs and many possible complications like organ
rejection, neoplasms, coronary artery disease of the graft, infections and renal failure. The
indications and contraindications are well codified [16]. There is no randomised study; how-
ever, survival and quality of life are greatly improved. Management of immunosuppressant
medications is of outmost importance.
6. Conclusion
Heart failure is a worldwide health issue; however, new diagnostic modalities, drugs, devices
and multidisciplinary approaches will certainly be able to better manage these complex patients.
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